ADAR1 Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-351,141
Closed -$79.4K – 307
2026
Q2
$79.4K Sell
351,141
-400,000
-53% -$241K ﹤0.01% 266
2026
Q1
$429K Buy
751,141
+127,566
+20% +$77.5K 0.03% 214
2025
Q4
$413K Buy
623,575
+510,513
+452% +$1.84M 0.03% 198
2025
Q3
$401K Sell
113,062
-307,703
-73% -$919K 0.04% 150
2025
Q2
$842K Hold
420,765
– – 0.13% 96
2025
Q1
$1.05M Buy
420,765
+299,304
+246% +$847K 0.2% 79
2024
Q4
$358K Sell
121,461
-41,617
-26% -$117K 0.07% 129
2024
Q3
$491K Buy
+163,078
New +$556K 0.08% 118
2024
Q2
– Sell
-89,938
Closed -$475K – 316
2024
Q1
$475K Sell
89,938
-155,564
-63% -$748K 0.11% 85
2023
Q4
$1.26M Buy
+245,502
New +$929K 0.45% 38

Other funds holding VTGN

ADAR1 Capital Management's VTGN Position: Q3 2026 in Review

ADAR1 Capital Management sold out of VistaGen Therapeutics (VTGN) in Q3 2026, closing a stake of 351,141 shares — an estimated $79.4K sold.

ADAR1 Capital Management first reported a position in VTGN in Q4 2023 and held it in 10 quarters. The position peaked at $1.26M in Q4 2023. 42 funds tracked by Wall St. Rank hold VTGN as of Q3 2026.

  • ADAR1 Capital Management reported no remaining VistaGen Therapeutics position as of Q3 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 351,141 VistaGen Therapeutics shares in Q3 2026, an estimated $79.4K.
  • ADAR1 Capital Management first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 10 quarters.
  • ADAR1 Capital Management's VistaGen Therapeutics position peaked at $1.26M in Q4 2023.
  • 42 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2026.

Based on ADAR1 Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.